glp 1 news today Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease GLP-1 Pipeline Update: November 2025

HRT and GLP-1: What Women Need to Know About Combining These Therapies At a glance Primary GLP-1 agents used with HRT / semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) Mean weight loss with semaglutide 2.4 mg / 14.9% at 68 weeks in STEP-1 (N=1,961) Estrogen effect on visceral fat / transdermal 17-beta-estradiol reduces visceral adiposity by ~6-7% vs placebo per RCT data Oral estrogen risk with GLP-1 / slowed gastric emptying may reduce absorption

Safety Although many animal studies have looked into the potential therapeutic benefits of IGF-1 LR3, human studies are still lacking

Revitalize Health Research is a chemical supplier

They found that when people stop these medications after an average of 39 weeks of treatment, they generally regain weight rapidly, and their cardiometabolic markers return to pre-GLP-1 levels by 1.4 years after treatment has been discontinued

Neurons were stimulated with Dihexa or Nle'-AnglV over a 5 day period at a wide range of concentrations

And your mouth pays the price